Showing results (241-250 of 417) with videos related to

Sort By:
Pageof 42
Plos One|August 10, 2019
Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and functionMarina Ollé Hurtado, Jolien Wolbert, Jonathan Fisher, et al.
ANZ Journal of Surgery|June 20, 2002
Australian audit for the endoluminal repair of abdominal aortic aneurysm: the first 12 monthsMaggi Boult, Wendy Babidge, John Anderson, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 19, 2019
Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched AnalysisÁdám G Tabák, John Anderson, Pablo Aschner, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 2, 2023
A Phase I Trial of Allogeneic γδ T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid LeukemiaJan Vydra, Emilio Cosimo, Petr Lesný, et al.
Oncology Reports|May 23, 2019
Engineered human mesenchymal stem cells for neuroblastoma therapeuticsValentina Nieddu, Roberta Piredda, Daniel Bexell, et al.
The Journal of Antimicrobial Chemotherapy|August 18, 2011
Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and WalesStephanie A Chisholm, Sarah Alexander, Leah Desouza-Thomas, et al.
Diabetes, Obesity & Metabolism|August 11, 2025
Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational studyRayaz A Malik, John Anderson, Giuseppina Russo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtypeDaniel Williamson, Yong-Jie Lu, Tony Gordon, et al.
Pageof 42